(NASDAQ: CCCC) C4 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
C4 Therapeutics's earnings in 2026 is -$104,994,000.On average, 10 Wall Street analysts forecast CCCC's earnings for 2026 to be -$144,142,480, with the lowest CCCC earnings forecast at -$359,556,059, and the highest CCCC earnings forecast at -$79,916,525. On average, 10 Wall Street analysts forecast CCCC's earnings for 2027 to be -$105,052,663, with the lowest CCCC earnings forecast at -$137,702,321, and the highest CCCC earnings forecast at -$69,670,817.
In 2028, CCCC is forecast to generate -$133,935,803 in earnings, with the lowest earnings forecast at -$228,547,601 and the highest earnings forecast at -$81,965,667.